<DOC>
	<DOCNO>NCT02204332</DOCNO>
	<brief_summary>The purpose study determine efficacy safety cabazitaxel administration patient colorectal cancer resistant standard treatment .</brief_summary>
	<brief_title>Phase II-b Randomized Clinical Trial Cabazitaxel Metastatic Colorectal Cancer Resistant Standard Treatment</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Patients give write informed consent . Men woman age ≥ 18 year . Patients histologically confirm metastatic advanced colorectal cancer without possibility potentially curative treatment . Patients life expectancy three month . Patients advanced colorectal cancer progression receive standard treatment . Patients grade 02 functional status , accord Eastern Cooperative Oncology Group ( ECOG ) . Patients evaluable tumor RECIST criterion . Patients recover degree less equal 1 , baseline important pretreatmentrelated AEs ( exclude alopecia ) . Ability willingness patient consent participation study . Ability understand comply study procedure . Patients performance status great 2 , Eastern Cooperative Oncology Group ( ECOG ) . Inadequate marrow reserve , within 7 day prior randomization : absolute neutrophil count &lt; 1.5 x 109 / L Hemoglobin &lt; 9.0 g / dL Platelet count &lt; 100 x 109 / L Inadequate liver function within 7 day prior randomization : AST ( SGOT ) ALT ( SGPT ) &gt; 3.0 x ULN 5 &gt; x ULN case abnormal liver function due underlie liver metastasis . Alkaline phosphatase &gt; 3 × ULN ( 5 time ULN due underlie liver metastasis ) . Total bilirubin &gt; 1.5 x ULN . Previous history malignancy , except skin basal squamous cell cancer proper treatment , situ cervical cancer , cancer , patient free disease last 5 year . Simultaneous treatment concomitant anticancer therapy . History brain metastasis , uncontrolled compression spinal cord , carcinomatous meningitis , new evidence brain leptomeningeal disease pathology . Acquired Immunodeficiency Syndrome ( AIDSrelated diseases ) human immunodeficiency virus ( HIV ) condition require antiretroviral therapy virus . symptomatic grade ≥ 2 peripheral sensory neuropathy , accord NCICTCAE v4.0 . Any severe acute chronic medical condition may affect patient 's ability participate study , may lead unacceptable security risk noncompliance protocol procedure may interfere interpretation study result . Pregnant woman breastfeed . Pregnancy assessment conduct test serum urine 7 day prior randomization . Patient ( male female ) reproductive age still disagree use effective contraception treatment period least 3 month completion treatment period study . The definition `` effective method birth control '' opinion investigator . Participation another clinical trial investigational drug / investigational drug adjunctive therapy within 30 day prior randomization . Concomitant treatment prohibit drug potent inhibitor inducer cytochrome P450 3A4 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>